Recently, two distinct hepatitis C virus (HCV) serologic types 
genotype, and 6 were nonviremic. Seventy-four patients had been exposed to serotype 2: 64 were infected with genotype 111, 3 were infected with mixed genotypes, 2 were infected with an indeterminate genotype, and 5 were nonviremic. The serum of one patient, infected with genotype III, showed reactivity to both serotypes. Comparative evaluation of HCV core region serotyping and genotyping with sera from 294 viremic patients infected with a known HCV genotype showed a remarkable concordance between HCV core region genotyping and serotyping, with only 2 apparently discordant serum samples (both from patients with genotype III infection) of 148 (1.4%) successfully serotyped samples. Serotype 1 infection was more frequently observed in patients with overt chronic liver disease and accounted for all successfully serotyped samples from intravenous drug abusers. In contrast, serotype 2 was more prevalent in subjects with biochemically silent HCV infection (alanine aminotransferase, <45 U/liter), in agreement with previous findings at the molecular level. HCV core serologic typing is a simple, inexpensive, and highly reproducible assay that can be applied to more than 50% of viremic HCV antibody carriers prior to the use of more sophisticated molecular typing techniques. Moreover, it may be helpful in tracking transmission routes, particularly for incorrectly stored samples in which the RNA has degraded or for subjects who have cleared the virus and therefore have only antibodies remaining to testify to a remote infection. The lack of recognition of the core sequence from residues 67 to 81, which contains a minor B-cell epitope used to detect type-specific immunoreactivity, may explain the negative serologic findings for half of the patients.
Hepatitis C virus (HCV) is a highly heterogeneous, singlestranded RNA virus which frequently causes persistent infection leading to chronic liver disease and primary hepatocellular carcinoma (1, 5, 11, 12) . Several HCV types have been identified on the basis of nucleotide and amino acid diversities among viral isolates worldwide (3, 7, 14, 16, 17, (22) (23) (24) . Specific HCV genotypes have been associated with the histologic severity of chronic hepatitis (7, 27) and the response to interferon therapy (28) (14) or PCR amplification of specific core sequences with type-specific primers, as described by Okamoto et al., respectively (16, 17) . Comparative sequence analysis showed that types I, II, III, IV, V, and VI of Okamoto et al. (16, 17) correspond to types la, lb, 2a, 2b, 3a, and 3b of Simmonds et al., respectively (22 studied had been transfused with blood or blood products, and of these, 40 were in remission from ALL, 32 were on hemodialysis, 13 were asymptomatic subjects with ALT levels of <45 U/liter, 9 had CLD, and 2 had HCC. Ten patients (3%), eight with CLD and two with persistently normal ALT levels, were health care workers. Patients with ALT levels persistently less than 45 U/liter were followed up for a median of 26 months (range, 10 to 46 months) with bimonthly ALT determinations. A liver biopsy was performed on 118 patients: 19 IVDAs, 34 asymptomatic HCV RNA-positive patients with ALT levels of <45 U/liter, and 65 patients with biochemical evidence of chronic liver disease. Details of the histologic diagnosis for the patients in these categories are reported in Table 1 .
Detection of HCV RNA and genotyping. HCV RNA was initially detected by nested reverse transcription PCR by using conserved primers localized in the 5' NC region of the viral genome (9, 19 ) by using RNA extracted from 100 ,ul of serum.
HCV genotyping was performed by PCR amplification of core region sequences with universal primers and five type-specific primers to generate DNA fragments with a size specific for each of the five most common HCV genotypes (16, 17) . The genotype III-specific primer was modified (5'-GCCCCAT GAAGGGCGAGAAC-3') because of several nucleotide differences in the genotype III sequence between Italian and Japanese isolates (19, 21) . The sequence of the primer was derived after cloning and sequencing of the core gene from 18 indeterminate serum samples. The newly designed type IIIspecific primer was very efficient, with an overall number of nontypeable samples reproducibly less than 5% (19, 21) . Genotyping fidelity was confirmed by cloning and sequencing of the 5' NC, core, and NS5 regions from representative clones classified according to the modified procedure. HCV genotypes I, II, III, IV, and V accounted, alone or in combination, for the majority of circulating viruses in our geographic area.
HCV core serotyping. HCV core serologic typing was performed by the method of Machida et al. (13); the method is based on differential antibody recognition of a genotypespecific variable region encompassing residues 68 to 78 of the deduced amino acid sequence of HCV, with minor modifications. Briefly, since no significant differences in recognition of shorter peptides were observed in the previous study (13) , the N-terminal isoleucine and proline residues were deleted from the original 17-mer peptides to obtain the following two 15-mer peptides comprising residues 67 to 81: N-KARR PEGRTWAQPGY-C (pl), which defines serotype 1, and N-KDRRSTGKSWGKPGY-C (p2j), which defines serotype 2.
However, because of the limited, although significant, nucleotide diversities among Italian and Japanese genotype III isolates reported above, which were responsible for specific amino acid differences within serotype 2, we synthesized a modified 15-mer (p2i) containing two substitutions, threonine and arginine at positions 71 and 78, respectively: N-KDRRT TGKSWGRPGY-C. Peptides were purchased from Chiron Mimotopes Pty. Ltd. (Clayton, Victoria, Australia). Purity was greater than 95% by analytical high-pressure liquid chromatography.
Lyophilized peptides were dissolved in 0.1% trifluoroacetic acid-30% acetonitrile in water to a concentration of 1 mg/ml and were further diluted to 5 ,ug/ml in 0.01 M bicarbonate buffer (pH 9.6). One hundred microliters of peptide solution was subsequently added to each well of an enzyme immunoassay microtitration plate (Linbro; Flow Laboratories), and the plate was incubated overnight at 4°C. Wells were then blocked with 0.01 M phosphate-buffered saline containing 0.137 M NaCl (pH 7.2) supplemented with 10% heat-inactivated newborn calf serum and 0.05% Tween 20 (PNT). After extensive washing with PNT, sera were diluted 1/5 to 1/10 and were incubated for 1 h at 37°C. After a further washing with PNT, peroxidase-conjugated rabbit anti-human immunoglobulin G was added to the wells for another hour. The reaction was then developed with ortho-phenylendiamine-HCl as the substrate. Sera from 25 healthy subjects served as controls. The mean A492values for negative controls were as follows: pl, 0.140 ± 0.065; p2i, 0.148 ± 0.071; and p2i, 0.148 ± 0.066. The upper limit of normal in such a system, 3 standard deviation above the mean value for negative controls for each peptide, was 0.335 for pl, 0.361 for p2j, and 0.346 for p21. The absorbance values for each serum sample were highly reproducible, and intra-and interassay variations were minimal and not significant.
Statistical analysis. The x2 or Fisher exact tests were used, as appropriate, for statistical analysis of differences. 
RESULTS
HCV RNA and genotype. HCV RNA was detected in 309 (85%) of the 363 anti-HCV positive patients by using primers from the 5' NC region of the genome. Of 54 patients with undetectable viremia by this method, 31 were subjects with ALT levels of <45 U/liter, 10 were on chronic hemodialysis, 10 were children in remission from ALL, and 3 were IVDAs. The HCV genotype was successfully identified in 294 (95%) of the 309 viremic patients by using five type-specific primers from the core region: 42 were IVDAs, 24 were hemodialysis patients, 28 were in remission from ALL, 90 were asymptomatic anti-HCV-positive subjects with normal or near normal ALT levels, 87 were patients with biochemical evidence of CLD, and 23 were patients with HCC.
HCV core serotype. The HCV core serotype was identified in 164 (45%) of the 363 patients studied. The efficiency of recognition of the core sequence encompassing residues 67 to 81 (67-81°re) was higher in viremic patients, particularly those in whom the HCV genotype could be defined: 148 of 294 (50%) compared with 11 (20%) of 54 subjects who were nonviremic at the time of the study (X2 = 15.33 with one degree of freedom; P < 0.0001). Moreover, among patients showing positive immunoreactivity for serotype-specific peptides, mean A492 values were higher in PCR-positive than in PCR-negative patients (1.861 ± 0.892 for pl and 1.671 ± 0.0.767 for p2i versus 1.240 ± 0.720 for pl and 1.402 ± 0.896 for p2i, respectively). Comparative evaluation of HCV core serotyping and genotyping showed that 80 of 148 (54%) patients had evidence of exposure to serotype 1 and that 78 of these were infected with genotypes I, II, and V, either alone or in combination, whereas only two patients infected with genotype III were classified as serotype 1 reactive (Table 2 ). In addition, 67 of 148 (45.3%) subjects infected with genotype III, either isolated or in combination, had been exposed to serotype 2 and 1 patient (0.7%), apparently infected with genotype III alone, showed reactivity for both serotype-specific peptides ( There were no significant differences in terms of serotyping efficiency among patient categories, although the proportion of sera from children in remission from ALL reactive with core peptides tended to be marginally lower than average (Table 3) . Contingency table analysis of serotype distribution among patient categories revealed statistically significant differences (Table 3) . Thus, serotype 2 infection was more prevalent in children with previous ALL and in patients with normal or near-normal ALT levels and was never found in IVDAs, in keeping with preliminary findings showing predominant infections with genotypes I and V in the IVDA patient category (20) . In contrast, serotype 1 infection was more frequently found in patients presenting with typical CLD and hemodialysis patients and accounted for all successfully serotyped HCV infections in IVDAs. Statistically significant differences in core serotype distribution were also found between patients with and without elevated ALT levels (x2 = 10.28 with 2 degrees of freedom; P < 0.01). Indeed, the prevalence of HCV serotype 2 infection was significantly higher in patients with normal or near-normal ALT levels than in those with persistently abnormal ALT levels ( 
DISCUSSION
The findings of the large survey reported here indicate that HCV core serotyping is a simple, inexpensive, and reproducible supplemental assay than can be successfully applied to approximately one-half of viremic anti-HCV-positive subjects. The relatively inefficient recognition of 67-81Core residues is conceivably due to the existence of a minor B-cell epitope within this sequence. To this end, we and others have shown that the amino-terminal region of the viral nucleocapsid protein contains at least two major antibody-binding sites that are recognized by virtually all HCV-infected patients (2, 8, 15, 18) . Unfortunately, the immunodominant N-terminal core subregion seems to be inadequate for serologic typing, since it is highly conserved among viral isolates (11) .
There was a remarkable concordance between HCV genotyping and core serotyping, with only 1% apparently discordant serum samples, indicating that our findings were highly reproducible both at the molecular and at the immunologic levels and further strengthening the results obtained previously by using core region genotyping (21) . The proportion of successfully serotyped patients, however, was slightly lower than that originally reported by Machida and coworkers (13) in a limited number of patients. The reasons for such discrepancies are not immediately apparent and may be related to geographic variations or the stringency used in the serotyping assay. The reduction in the original length of the peptides cannot be advocated as a cause of diminished immunoreactivity, since deletions of up to six N-terminal residues had no effect on epitope recognition (13 (21) . Although serologic typing was significantly less efficient than molecular typing, it is of interest that the genotyping data were largely confirmed by serologic typing. Our observations are compatible with previous studies in which the severity of histologic lesions (7, 27) and poor responses to interferon treatment (28) were associated with specific HCV genotypes. More recently, a clear relationship between HCV serotypes and response to interferon treatment has been demonstrated (4). The biological basis of such findings may be explained on the grounds of the nucleotide diversities among genotypes in putative regulatory regions at the 5' and 3' ends of the viral genome (10, 11) , which may have potential pathogenetic implications, as suggested previously for other RNA viruses (26) .
Although the serologic assay for the detection of typespecific antibodies does not necessarily document ongoing infection, it is clearly a practical alternative to current PCRbased typing assays in at least 50% of viremic patients and represents the only possible assay in those who are anti-HCV positive, HCV RNA negative by PCR. The relatively small proportion (20%) of positive samples in these subjects suggests, however, that immune responses to the HCV core peptides used in this assay are probably short-lasting following viral clearance. Nevertheless, HCV serotyping may be helpful in tracking transmission routes, particularly for incorrectly stored samples in which the RNA has degraded or for infected hosts who have cleared the virus and therefore have only antibodies remaining to testify to a remote infection. This last issue may probably be better addressed by core typing rather than NS4 typing, since NS4 antibodies are generally lost after viral clearance (6) .
